Patterns of epidermal growth factor receptor testing across 111 tertiary care centers in India: Result of a questionnaire-based survey
Background: We conducted a survey of 111 medical oncologists across India to understand the current pattern of epidermal growth factor receptor (EGFR) mutation testing at their respective centers. Methods: Medical oncologists from 111 institutes across India were interviewed face to face using a str...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2018-01-01
|
| Series: | South Asian Journal of Cancer |
| Subjects: | |
| Online Access: | http://journal.sajc.org/article.asp?issn=2278-330X;year=2018;volume=7;issue=3;spage=203;epage=206;aulast=Prabhash |
| _version_ | 1818933752801263616 |
|---|---|
| author | Kumar Prabhash Purvish M Parikh Senthil J Rajappa Vanita Noronha Amit Joshi Shyam Aggarwal Shailesh Bondarde Shekar Patil Chirag Desai Palanki Satya Dattatreya Rajesh Naik Sohit Anand Raju Titus Chacko Ghanshyam Biswas Tarini P Sahoo Deepak Dabkara Vijay Patil M V Chandrakant Pratap K Das Ashok K Vaid Dinesh C Doval |
| author_facet | Kumar Prabhash Purvish M Parikh Senthil J Rajappa Vanita Noronha Amit Joshi Shyam Aggarwal Shailesh Bondarde Shekar Patil Chirag Desai Palanki Satya Dattatreya Rajesh Naik Sohit Anand Raju Titus Chacko Ghanshyam Biswas Tarini P Sahoo Deepak Dabkara Vijay Patil M V Chandrakant Pratap K Das Ashok K Vaid Dinesh C Doval |
| author_sort | Kumar Prabhash |
| collection | DOAJ |
| description | Background: We conducted a survey of 111 medical oncologists across India to understand the current pattern of epidermal growth factor receptor (EGFR) mutation testing at their respective centers. Methods: Medical oncologists from 111 institutes across India were interviewed face to face using a structured questionnaire. They were divided into two groups – Group 1 with in-house EGFR testing and Group 2 who send samples to central/commercial laboratories outside their institutions. Answers of the two groups were analyzed to see the prevailing patterns of EGFR testing and differences between the two groups if any. Results: Ninety-five percent (105/111) of medical oncologists recommended testing for EGFR mutations in patients with adenocarcinoma histology and 40% (44/111) recommended EGFR testing in squamous cell histology. The average time duration to get EGFR test results was 10 days in Group 1 centers versus 18 days in Group 2 centers. Ninety-six percent (106/111) of the medical oncologists from Group 1 centers requested for factoring additional sample for biomarker testing compared to 69% (77/111) of the oncologists from Group 2 centers. Sixty-nine percent (77/111) of medical oncologists in Group 1 centers would prefer to wait for the test results before initiating treatment compared to 46% (51/111) in Group 2. EGFR tyrosine-kinase inhibitors were used in only approximately 60% of patients with diagnosed EGFR mutation in the first line. For patients in whom chemotherapy was initiated while waiting for test results, 50% (56/111) of medical oncologists would prefer to complete 4–6 cycles before switching to targeted therapy. At the time of progression, rebiopsy was possible in approximately 25% of the patients. Conclusions: Turnaround time for molecular testing should improve so that eligible patients can benefit from targeted therapies in the first line. There is a need to increase the awareness among pulmonologists, oncologists, and interventional radiologists regarding the importance of adequate samples required for molecular tests. |
| first_indexed | 2024-12-20T04:53:23Z |
| format | Article |
| id | doaj.art-9c56a13472af45e7bd686d8f8d371f70 |
| institution | Directory Open Access Journal |
| issn | 2278-330X |
| language | English |
| last_indexed | 2024-12-20T04:53:23Z |
| publishDate | 2018-01-01 |
| publisher | Thieme Medical and Scientific Publishers Pvt. Ltd. |
| record_format | Article |
| series | South Asian Journal of Cancer |
| spelling | doaj.art-9c56a13472af45e7bd686d8f8d371f702022-12-21T19:52:47ZengThieme Medical and Scientific Publishers Pvt. Ltd.South Asian Journal of Cancer2278-330X2018-01-017320320610.4103/sajc.sajc_30_18Patterns of epidermal growth factor receptor testing across 111 tertiary care centers in India: Result of a questionnaire-based surveyKumar PrabhashPurvish M ParikhSenthil J RajappaVanita NoronhaAmit JoshiShyam AggarwalShailesh BondardeShekar PatilChirag DesaiPalanki Satya DattatreyaRajesh NaikSohit AnandRaju Titus ChackoGhanshyam BiswasTarini P SahooDeepak DabkaraVijay PatilM V ChandrakantPratap K DasAshok K VaidDinesh C DovalBackground: We conducted a survey of 111 medical oncologists across India to understand the current pattern of epidermal growth factor receptor (EGFR) mutation testing at their respective centers. Methods: Medical oncologists from 111 institutes across India were interviewed face to face using a structured questionnaire. They were divided into two groups – Group 1 with in-house EGFR testing and Group 2 who send samples to central/commercial laboratories outside their institutions. Answers of the two groups were analyzed to see the prevailing patterns of EGFR testing and differences between the two groups if any. Results: Ninety-five percent (105/111) of medical oncologists recommended testing for EGFR mutations in patients with adenocarcinoma histology and 40% (44/111) recommended EGFR testing in squamous cell histology. The average time duration to get EGFR test results was 10 days in Group 1 centers versus 18 days in Group 2 centers. Ninety-six percent (106/111) of the medical oncologists from Group 1 centers requested for factoring additional sample for biomarker testing compared to 69% (77/111) of the oncologists from Group 2 centers. Sixty-nine percent (77/111) of medical oncologists in Group 1 centers would prefer to wait for the test results before initiating treatment compared to 46% (51/111) in Group 2. EGFR tyrosine-kinase inhibitors were used in only approximately 60% of patients with diagnosed EGFR mutation in the first line. For patients in whom chemotherapy was initiated while waiting for test results, 50% (56/111) of medical oncologists would prefer to complete 4–6 cycles before switching to targeted therapy. At the time of progression, rebiopsy was possible in approximately 25% of the patients. Conclusions: Turnaround time for molecular testing should improve so that eligible patients can benefit from targeted therapies in the first line. There is a need to increase the awareness among pulmonologists, oncologists, and interventional radiologists regarding the importance of adequate samples required for molecular tests.http://journal.sajc.org/article.asp?issn=2278-330X;year=2018;volume=7;issue=3;spage=203;epage=206;aulast=PrabhashAnaplastic lymphoma kinasebiopsyepidermal growth factor receptorfine-needle aspiration cytologynon-small cell lung cancer |
| spellingShingle | Kumar Prabhash Purvish M Parikh Senthil J Rajappa Vanita Noronha Amit Joshi Shyam Aggarwal Shailesh Bondarde Shekar Patil Chirag Desai Palanki Satya Dattatreya Rajesh Naik Sohit Anand Raju Titus Chacko Ghanshyam Biswas Tarini P Sahoo Deepak Dabkara Vijay Patil M V Chandrakant Pratap K Das Ashok K Vaid Dinesh C Doval Patterns of epidermal growth factor receptor testing across 111 tertiary care centers in India: Result of a questionnaire-based survey South Asian Journal of Cancer Anaplastic lymphoma kinase biopsy epidermal growth factor receptor fine-needle aspiration cytology non-small cell lung cancer |
| title | Patterns of epidermal growth factor receptor testing across 111 tertiary care centers in India: Result of a questionnaire-based survey |
| title_full | Patterns of epidermal growth factor receptor testing across 111 tertiary care centers in India: Result of a questionnaire-based survey |
| title_fullStr | Patterns of epidermal growth factor receptor testing across 111 tertiary care centers in India: Result of a questionnaire-based survey |
| title_full_unstemmed | Patterns of epidermal growth factor receptor testing across 111 tertiary care centers in India: Result of a questionnaire-based survey |
| title_short | Patterns of epidermal growth factor receptor testing across 111 tertiary care centers in India: Result of a questionnaire-based survey |
| title_sort | patterns of epidermal growth factor receptor testing across 111 tertiary care centers in india result of a questionnaire based survey |
| topic | Anaplastic lymphoma kinase biopsy epidermal growth factor receptor fine-needle aspiration cytology non-small cell lung cancer |
| url | http://journal.sajc.org/article.asp?issn=2278-330X;year=2018;volume=7;issue=3;spage=203;epage=206;aulast=Prabhash |
| work_keys_str_mv | AT kumarprabhash patternsofepidermalgrowthfactorreceptortestingacross111tertiarycarecentersinindiaresultofaquestionnairebasedsurvey AT purvishmparikh patternsofepidermalgrowthfactorreceptortestingacross111tertiarycarecentersinindiaresultofaquestionnairebasedsurvey AT senthiljrajappa patternsofepidermalgrowthfactorreceptortestingacross111tertiarycarecentersinindiaresultofaquestionnairebasedsurvey AT vanitanoronha patternsofepidermalgrowthfactorreceptortestingacross111tertiarycarecentersinindiaresultofaquestionnairebasedsurvey AT amitjoshi patternsofepidermalgrowthfactorreceptortestingacross111tertiarycarecentersinindiaresultofaquestionnairebasedsurvey AT shyamaggarwal patternsofepidermalgrowthfactorreceptortestingacross111tertiarycarecentersinindiaresultofaquestionnairebasedsurvey AT shaileshbondarde patternsofepidermalgrowthfactorreceptortestingacross111tertiarycarecentersinindiaresultofaquestionnairebasedsurvey AT shekarpatil patternsofepidermalgrowthfactorreceptortestingacross111tertiarycarecentersinindiaresultofaquestionnairebasedsurvey AT chiragdesai patternsofepidermalgrowthfactorreceptortestingacross111tertiarycarecentersinindiaresultofaquestionnairebasedsurvey AT palankisatyadattatreya patternsofepidermalgrowthfactorreceptortestingacross111tertiarycarecentersinindiaresultofaquestionnairebasedsurvey AT rajeshnaik patternsofepidermalgrowthfactorreceptortestingacross111tertiarycarecentersinindiaresultofaquestionnairebasedsurvey AT sohitanand patternsofepidermalgrowthfactorreceptortestingacross111tertiarycarecentersinindiaresultofaquestionnairebasedsurvey AT rajutituschacko patternsofepidermalgrowthfactorreceptortestingacross111tertiarycarecentersinindiaresultofaquestionnairebasedsurvey AT ghanshyambiswas patternsofepidermalgrowthfactorreceptortestingacross111tertiarycarecentersinindiaresultofaquestionnairebasedsurvey AT tarinipsahoo patternsofepidermalgrowthfactorreceptortestingacross111tertiarycarecentersinindiaresultofaquestionnairebasedsurvey AT deepakdabkara patternsofepidermalgrowthfactorreceptortestingacross111tertiarycarecentersinindiaresultofaquestionnairebasedsurvey AT vijaypatil patternsofepidermalgrowthfactorreceptortestingacross111tertiarycarecentersinindiaresultofaquestionnairebasedsurvey AT mvchandrakant patternsofepidermalgrowthfactorreceptortestingacross111tertiarycarecentersinindiaresultofaquestionnairebasedsurvey AT pratapkdas patternsofepidermalgrowthfactorreceptortestingacross111tertiarycarecentersinindiaresultofaquestionnairebasedsurvey AT ashokkvaid patternsofepidermalgrowthfactorreceptortestingacross111tertiarycarecentersinindiaresultofaquestionnairebasedsurvey AT dineshcdoval patternsofepidermalgrowthfactorreceptortestingacross111tertiarycarecentersinindiaresultofaquestionnairebasedsurvey |